NanoVibronix

82 articles about NanoVibronix

• NanoVibronix Provides Update on Expanding Access to PainShield

  1/18/2023

  NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided an update on the efforts to expand access to the Company’s PainShield product.

• NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today - December 15,2022

  12/15/2022

  NanoVibronix, Inc. announced that the Company’s 2022 annual meeting of stockholders (the “Annual Meeting”) was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022.

• NanoVibronix Announces Partnership with Peak Medical, Ltd.

  12/13/2022

  NanoVibronix, Inc . (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has partnered with Peak Medical, Ltd., a continence care patient focused company based in the United Kingdom.

• NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  11/29/2022

  NanoVibronix, Inc. today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 4,800,000 shares of its common stock.

• NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

  11/28/2022

  NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

• NanoVibronix Announces Interim Results of Clinical Study for UroShield

  11/16/2022

  NanoVibronix, Inc today announced interim results of its U.K. clinical study for UroShield that is being conducted by The University of Southampton and the National Biofilms Innovation Centre.

• NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

  10/19/2022

  NanoVibronix, Inc today announced that on October 17, 2022, a Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on The Nasdaq Capital Market.

• NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract

  9/23/2022

  NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract.

• NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

  9/14/2022

  NanoVibronix, Inc. today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share.

• NanoVibronix Sets Date for Annual Shareholder Meeting

  9/14/2022

  NanoVibronix, Inc . , (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022.

• NanoVibronix Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

  9/2/2022

  NanoVibronix, Inc. announced that, on August 30, 2022, the Company received notice from the Nasdaq Listing Qualifications Staff indicating that, based upon the Company’s continued non-compliance with Nasdaq’s minimum bid price requirement as of August 29, 2022, the Company securities would be subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel.

• NanoVibronix Provides Business Update in Letter to Shareholders

  8/18/2022

  NanoVibronix, Inc., a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave technology, provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian Murphy.

• NanoVibronix Announces Webinar Series to Promote UroShield

  7/12/2022

  NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced its Australian distributor, DukeHill HC, is launching a series of educational webinars to present the Company’s UroShield technology to clinicians.

• NanoVibronix Strengthening Supply Chain Increasing Efficiency and Scalability

  6/29/2022

  NanoVibronix, Inc . (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it is shifting the majority of its manufacturing operations to Singapore in order to allow scalability increase efficiency and address potential supply chain delays.

• NanoVibronix Reports First Quarter 2022 Financial Results

  5/17/2022

  NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022.

• NanoVibronix Announces FDA 510(k) Submission for PainShield® MD PLUS

  5/4/2022

  NanoVibronix, Inc. today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

• NanoVibronix Adds Additional Product to Federal Supply Schedule

  4/25/2022

  NanoVibronix, Inc. today announced that its PainShield Plus and PainShield Monthly Kit products have been added to the Federal Supply Schedule (FSS) through a service disabled veteran organization.

• NanoVibronix Advances Efforts to Achieve NHS Approval

  4/5/2022

  NanoVibronix, Inc. today announced that it has received the publication of Guidance from the National Institute for Health and Care Excellence (NICE) with recommendations of the company’s UroShield device.

• NanoVibronix Announces PainGuard and UroGuard Approved by Health Canada as Licensed Medical Devices

  3/30/2022

  NanoVibronix, Inc. today announced the Company’s PainGuard and UroGuard, offered as private label products through Ideal Medical International Limited, have been approved by Health Canada.

• NanoVibronix Extends Reach of UroShield and PainShield through MTSG’s International Network

  1/24/2022

  NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions Group (“MTSG”), a leader in the commercialization of healthcare technologies.